BRISTOL MYERS SQUIBB CO
Add to watch list Add to watch list

Company

profile

overview

growth

risk

operations

valuation

Statements

income

balance sheet

cash flows

Insiders

Buzz Board

  • Compare against:
  • Note: Not all companies will have their earnings statement processed. see following for details. About us

BRISTOL MYERS SQUIBB CO Earnings Overview

Company overview section gives a snap shot of company and stock performance to quickly determine if the company is worth looking into.

It contains the stock performance overview, and stock volatility expressed in terms of stock turnover ratio (i.e. the average amount of time investors are holding on to their stocks) to give insight into the general mood of investors.

Company perforance is expressed in terms of revenue, net income, cash flows, debt and equity and several risk parameters, to asses the risk/reward profile of the company.

Stock data
Ticker BMY
Industry Pharmaceutical Preparations
Market value $44,723,418,400
Price per share $26.08
52 week range $21.77 - $27.00
Dividend $4.91
Shares 1,714,855,000
P/E 4.21
EPS $6.19
Stock volatility ( Share turnover )
past week 161 days
past month 168 days
past year 105 days
Earnings ( values in Millions )200920082007200620052004200320022001199919981997199619951994199319921991
Revenue$18,808$17,715$18,193$17,256$19,207$19,380$18,653$18,106$17,987$16,878$15,061$16,701$15,065$13,767$11,984$11,413$11,156$10,571
Cost of sales$5,140$5,316$5,868$5,739$5,928$5,989$5,406$6,532$5,453$4,542$3,896$4,464$3,965$3,637$3,122$3,029$2,857$2,717
Gross profit$13,668$12,399$12,325$11,517$13,279$13,391$13,247$11,574$12,534$12,336$11,165$12,237$11,100$10,130$8,862$8,384$8,299$7,854
Sales, general and administrative$3,946$4,140$4,516$4,800$5,106$5,016$4,620$4,124$3,894$3,789$3,685$4,173$3,925$3,670$3,166$3,098$3,075$2,946
Research and development$3,647$3,512$3,457$2,991$2,746$2,563$2,279$2,375$4,955$1,759$1,506$1,385$1,276$1,199$1,108$1,128$1,083$983
Restructuring$136$215$183$59$32$104$26$14$506--$157$225--$310----$890--
Asset impairment--$349----------$379--------------------
Other expenses$3,754$3,069$1,780$1,941$1,782$1,883$1,793$2,031$1,376$1,630$2,380$2,241$1,946$2,596$2,117$1,755$1,291$1,263
Operating income$2,185$1,114$2,389$1,726$3,613$3,825$4,529$2,651$1,803$5,158$3,437$4,213$3,953$2,355$2,471$2,403$1,960$2,662
Other income$367$1,053$273$200$569$320--$30$597--$201$269$60$47$84$168$27$122
Net interest expense (income)----------------$182------------------
Income before taxes$2,552$2,167$2,662$1,926$4,182$4,145$4,529$2,681$2,218$5,158$3,638$4,482$4,013$2,402$2,555$2,571$1,987$2,784
Taxes$1,182$1,090$682$538$932$1,519$1,210$391$73$1,369$888$1,277$1,163$590$713$612$449$793
Minority interest$1,250$996($763)($440)($592)($521)($373)($303)($102)------------------
Income before extraordinary items$2,620$2,073$1,217$948$2,658$2,105$2,946$1,987$2,043$3,789$2,750$3,205$2,850$1,812$1,842$1,959$1,538$1,991
Equity in net income of unconsolidated entities$550$617$524$474$334$273$151$80--------------------
Discontinued operations$7,442$2,557$424$163$8$10$9$70$2,791$378$391----------$670$65
Cumulative effect of accounting change--------------------------------$246--
Net income$10,612$5,247$2,165$1,585$3,000$2,388$3,106$2,137$4,834$4,167$3,141$3,205$2,850$1,812$1,842$1,959$1,962$2,056